Related Experiment Videos
The effect of somatostatin on blood flow through coronary bypass grafts in anesthetized man
Insights
Intravenous somatostatin did not alter blood flow in coronary bypass grafts in patients undergoing surgery. This study indicates somatostatin has no significant impact on coronary hemodynamics in humans.
Area of Science:
- Cardiovascular Surgery
- Pharmacology
Background:
- Coronary artery bypass grafting (CABG) is a critical surgical procedure.
- Understanding the impact of vasoactive drugs on graft patency is essential.
Purpose of the Study:
- To investigate the effect of intravenous somatostatin on blood flow in aorto-coronary bypass grafts.
- To assess the hemodynamic impact of somatostatin in the context of cardiac surgery.
Main Methods:
- Studied 12 patients undergoing CABG surgery.
- Measured aorto-coronary bypass blood flow using electromagnetic flowmetry.
- Administered intravenous somatostatin at doses of 100 and 250 microgram/h.
Main Results:
- No significant changes in bypass blood flow were observed during or after somatostatin infusion.
- The administration of somatostatin did not affect coronary hemodynamics.
Conclusions:
- Intravenous somatostatin does not appear to influence blood flow through coronary bypass grafts.
- Somatostatin has no discernible effect on human coronary hemodynamics in this surgical setting.
Abstract:
The effect of intravenous somatostatin on blood flow through coronary bypass grafts was studied in 12 patients subjected to aorto-coronary bypass surgery. Aorto-coronary bypass blood flow was determined by means of electromagnetic blood flowmetry. No change was observed in the bypass blood flow, either during or after intravenous somatostatin at doses of 100 microgram/h and 250 microgram/h. These findings suggest that somatostatin has no effect on coronary haemodynamics in man.